Is there a link between guttate psoriasis and SARS-CoV-2? A series of three cases

Brazão, Cláudia; Alpalhão, Miguel; Aguado-Lobo, Marta; Antunes, Joana; Soares‐de‐Almeida, Luís; Filipe, Paulo

doi:10.1016/j.abd.2021.07.006

Cited by 3 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Shoenfeld et al suggested a possible role of vaccines (including COVID-19 vaccines) as triggers for relapse or onset of autoimmune diseases, due to the potential agonism of vaccines on TLRs 7/8 or 9 (65). Although extensive real-world experience is lacking, to date 46 cases of psoriasis relapses following vaccination with COVID-19 have been described in the literature (38)(39)(40)(41)(42)(43)(44)(45)(46)(47)(48)(49)(50)(51)(52)(53)(54).…”

Section: Risk Of Psoriasis Relapse In Response To the Vaccine-induced...mentioning

confidence: 99%

“…Although BNT162b2 was found to be 95% effective in preventing COVID-19 in global phase 2 and 3 studies (26), several concerns have been raised and investigated in several clinical trials and reports around impaired protective response (27-37) and psoriasis relapses after vaccine administration (38)(39)(40)(41)(42)(43)(44)(45)(46)(47)(48)(49)(50)(51)(52)(53)(54).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Immunogenicity of three doses of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologics

Graceffa

Sperati²,

Bonifati³

et al. 2022

Front. Med.

View full text Add to dashboard Cite

IntroductionPsoriasis has not been directly linked to a poor prognosis for COVID-19, yet immunomodulatory agents used for its management may lead to increased vulnerability to the dangerous complications of SARS-CoV-2 infection, as well as impair the effectiveness of the recently introduced vaccines. The three-dose antibody response trend and the safety of BNT162b2 mRNA vaccine in psoriasis patients treated with biologic drugs have remained under-researched.Materials and methodsForty-five psoriatic patients on biologic treatment were enrolled to evaluate their humoral response to three doses of BNT162b2. IgG titers anti-SARS-CoV-2 spike protein were evaluated at baseline (day 0, first dose), after 3 weeks (second dose), four weeks post-second dose, at the time of the third dose administration and 4 weeks post-third dose. Seropositivity was defined as IgG ≥15 antibody-binding units (BAU)/mL. Data on vaccine safety were also collected by interview at each visit.ResultsA statistically significant increase in antibody titers was observed after each dose of vaccine compared with baseline, with no significant differences between patients and controls. Methotrexate used in combination with biologics has been shown to negatively influence the antibody response to the vaccine. On the contrary, increasing body mass index (BMI) positively influenced the antibody response. No adverse effects were reported, and no relapses of psoriasis were observed in the weeks following vaccine administration in our study population.ConclusionsOur data are largely consistent with the recent literature on this topic confirming the substantial efficacy and safety of BNT162b2 mRNA vaccine on psoriatic patients treated with biologics of different types and support the recommendation to perform additional doses in this specific subgroup of patients.

show abstract

Section: Risk Of Psoriasis Relapse In Response To the Vaccine-induced...mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Immunogenicity of three doses of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologics

Graceffa

Sperati²,

Bonifati³

et al. 2022

Front. Med.

View full text Add to dashboard Cite

show abstract

“…Staphylococcus aureus, Helicobacter pylori and Borrelia burgdorferi), 57,58 viral infections (e.g. COVID-19, HIV, human papillomavirus, hepatitis B virus, hepatitis C virus, varicella-zoster virus, Epstein-Barr virus, chikungunya virus and coxsackievirus), [58][59][60][61][62][63][64][65][66][67][68][69][70][71] fungal infections (e.g. Malassezia species and Candida albicans), 58,72 vaccinations (e.g.…”

Section: Aetiopathogenesismentioning

confidence: 99%

Childhood guttate psoriasis: an updated review

Leung,

Barankin,

Lam

et al. 2023

DIC

View full text Add to dashboard Cite

Background Guttate psoriasis is common and affects 0.5–2% of individuals in the paediatric age group. This review aims to familiarize physicians with the clinical manifestations, evaluation, diagnosis and proper management of guttate psoriasis. Methods A search was conducted in July 2023 in PubMed Clinical Queries using the key term “guttate psoriasis”. The search strategy included all observational studies, clinical trials and reviews published within the past 10 years. The information retrieved from the search was used in the compilation of the present article. Results Guttate psoriasis typically presents with an abrupt onset of numerous, small, scattered, tear-drop-shaped, scaly, erythematous, pruritic papules and plaques. Sites of predilection include the trunk and proximal extremities. There may be a history of preceding streptococcal infection. Koebner phenomenon is characteristic. Guttate psoriasis may spontaneously remit within 3–4 months with no residual scarring, may intermittently recur and, in 40–50% of cases, may persist and progress to chronic plaque psoriasis. Given the possibility for spontaneous remission within several months, active treatment may not be necessary except for cosmetic purposes or because of pruritus. On the other hand, given the high rates of persistence of guttate psoriasis and progression to chronic plaque psoriasis, some authors suggest active treatment of this condition. Conclusion Various treatment options are available for guttate psoriasis. Triggering and exacerbating factors should be avoided if possible. Topical corticosteroids alone or in combination with other topical agents (e.g. tazarotene and vitamin D analogues) are the most rapid and efficient treatment for guttate psoriasis and are therefore the first-line treatment for mild cases. Other topical therapies include vitamin D analogues, calcineurin inhibitors, anthralin, coal tar and tazarotene. Ultraviolet phototherapy is the first-line therapy for moderate-to-severe guttate psoriasis, as it is more practical than topical therapy when treating widespread or numerous small lesions. Systemic immunosuppressive and immunomodulatory therapies (e.g. methotrexate, cyclosporine, retinoids, fumaric acid esters and biologics) may be considered for patients with moderate-to-severe guttate psoriasis who fail to respond to phototherapy and topical therapies.

show abstract

Tozinameran

2022

Reactions Weekly

View full text Add to dashboard Cite

Is there a link between guttate psoriasis and SARS-CoV-2? A series of three cases

Cited by 3 publications

References 5 publications

Immunogenicity of three doses of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologics

Immunogenicity of three doses of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologics

Childhood guttate psoriasis: an updated review

Tozinameran

Contact Info

Product

Resources

About